1194235-14-7

N-(2-Pyrazinylcarbonyl)-L-phenylalanyl-L-phenylalanine is an impurity of Bortezomib(B675700). Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.